Collaborators from Cornell Medical College, the Fred Hutchinson Cancer Research Center, and the New York Genome Center achieves superior circulating, cell-free DNA extraction using Omega Bio-tek’s Mag-Bind® cfDNA Kit
Research publication review and discussion: “Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring”, Nature Medicine.
Circulating, cell-free DNA (cfDNA) holds great clinical significance for non-invasive disease detection, diagnosis, and monitoring for tumor, cancer, or fetal DNA studies. Circulating DNA extraction is often challenging as they are found in low quantities, and accurate, consistent methods are needed to isolate the less abundant cfDNA with higher sensitivity. Cancer and oncology researchers worldwide use cfDNA analysis to advance oncological research and make informed treatment decisions. In this context, Omega Bio-tek has developed cfDNA extraction kits for both manual processing using silica spin columns and for automated, high-throughput workflows using magnetic beads. In this blog post, we will see how Omega’s Mag-Bind® cfDNA Kit played a vital role as the superior cfDNA extraction method used in a recent publication in Nature Medicine.
In July 2020, a group of researchers from prestigious institutions such as the Weil Cornell Medical College, New York; the Fred Hutchinson Cancer Research Center, Seattle; and the New York Genome Center published an article in Nature Medicine titled, “Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring.” Asaf Zviran et al. wrote about how low cfDNA abundance is a barrier and presented an orthogonal framework for cfDNA cancer monitoring via genome-wide mutational integration, enabling ultra-sensitive detection, overcoming the limitation of cfDNA abundance, and empowering treatment optimization in low-disease-burden oncology care.1
In this post, we will look at a general overview of this 37-page behemoth publication and note how Omega Bio-tek’s Mag-Bind® cfDNA Kit provided better performance and ease of use compared to other tested methods1 helping researchers with the challenges of low cfDNA abundance and using whole genome sequencing (WGS) for tumor burden tracking and post-operative disease detection.
1. Zviran et al. 2020. Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring. Nature Medicine; 1114: 1114-1124.